NCT00805740 - An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

CandidiasisFungemia

Interventions

DRUG

Active anidulafungin

Subjects in this arm will receive active anidulafungin and placebo caspofungin

DRUG

Active Caspofungin

Subjects in this arm will receive active caspofungin and placebo anidulafungin

Trial Locations (18)

1000

Pfizer Investigational Site, Brussels

1070

Pfizer Investigational Site, Brussels

1200

Pfizer Investigational Site, Brussels

1606

Pfizer Investigational Site, Sofia

2060

Pfizer Investigational Site, Antwerp

19713

Pfizer Investigational Site, Newark

19718

Pfizer Investigational Site, Newark

19801

Pfizer Investigational Site, Wilmington

48202

Pfizer Investigational Site, Detroit

143423

Pfizer Investigational Site, P/o Stepanovskoe, Krasnogorskiy District, Moscow Region

V6Z 1Y6

Pfizer Investigational Site, Vancouver

1081 HZ

Pfizer Investigational Site, Amsterdam

1091 AC

Pfizer Investigational Site, Amsterdam

6532 SZ

Pfizer Investigational Site, Nijmegen

3040-853

Pfizer Investigational Site, Coimbra

1150-199

Pfizer Investigational Site, Lisbon

014461

Pfizer Investigational Site, Bucharest

CH-1211

Pfizer Investigational Site, Geneva